Year: 2025
Type: article
Abstract: Elevated levels of low-density lipoprotein cholesterol (LDL-C) are a key risk factor for atherosclerosis and cardiovascular disease (CVD). Statins are the primary therapy recommended by the European Society of Cardiology for hyperlipidaemia. If LDL-C targets are not achieved with statins alone, additional treatments such as PCSK9 inhibitors (e.g. evolocumab and alirocumab) are considered. Statins reduce cholesterol synthesis by inhibiting HMG-CoA reductase, while PCSK9 inhibitors prevent LDL receptor degradation, thereby enhancing hepatic LDL-C clearance. Clinical trials and meta-analyses suggest that both drug classes are effective in reducing cardiovascular events, although statins have been shown to have a greater impact on all-cause and cardiovascular mortality. PCSK9 inhibitors are particularly beneficial for high-risk patients or those intolerant to statins. Emerging therapies such as inclisiran offer the advantage of reduced injection frequency. Both statins and PCSK9 inhibitors are generally well tolerated; the most common side effect of statins is muscle pain, while the most common side effect of PCSK9 inhibitors is an injection site reaction. No significant association with neurocognitive adverse effects has been found for either therapy. Overall, both statins and PCSK9 inhibitors play a crucial role in lipid management and cardiovascular disease prevention.
Author: Walter F. Riesen
Language: English
Subfield: Surgery
Field: Medicine
Domain: Health Sciences
Open Access status: diamond
OpenAlex ID: W4412828131